Clinical trials
catalyst calendar across sponsors →Studies where IKT is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
4 interventional
Held by 6 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, TWO SIGMA INVESTMENTS, LP, AQR CAPITAL MANAGEMENT LLC, CITADEL ADVISORS LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, +1 more) · FINRA short interest 21.5 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH)NCT07632898Incidence of Treatment-emergent adverse events (TEAEs), serious TEAEs, and TEAEs of special interestOpen-label · Treatment | Phase 3 | Not yet recruiting | Drug: IKT-001 | Pulmonary Arterial Hypertension (PAH) | 484 | 2030-06-30 | in 1,410 d | 2026-06-08 |
| An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)NCT07365332[Part A] To evaluate the effect on Pulmonary Vascular Resistance (PVR) in participants with WHO Group 1 PAH treated with IKT-001 compared to placeboRandomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: IKT-001, Placebo | Pulmonary Arterial Hypertension | 486 | Jun 2029 | ≤ 1,045 d | 2026-05-12 |
| A Phase 2 Study of IkT-001Pro in Pulmonary Arterial Hypertension (PAH)NCT06643143To evaluate the effect on PVR in participants with WHO functional class II-III PAH treated with IkT-001Pro compare to placeboRandomized · Quadruple-masked · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Study has undergone sponsorship and design changes. | Drug: IkT-001Pro, Placebo | Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | 0 | 2027-06-30 | in 314 d | 2025-06-13 |
| A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mgNCT05623774Exposure of imatinib after administration of IkT-001Pro and imatinib mesylate, as measured by area under the concentration-time curve for imatinib from time zero to last measurable concentration (AUC(0-last))Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Imatinib Mesylate, IkT-001Pro | CML | 64 | 2024-06-30actual | — | 2025-11-06 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19